MX2020004218A - Métodos y composiciones para inhibir las actividades biológicas de adam10. - Google Patents

Métodos y composiciones para inhibir las actividades biológicas de adam10.

Info

Publication number
MX2020004218A
MX2020004218A MX2020004218A MX2020004218A MX2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A
Authority
MX
Mexico
Prior art keywords
adam10
biological activities
methods
peptides
inhibiting
Prior art date
Application number
MX2020004218A
Other languages
English (en)
Spanish (es)
Inventor
Marcia L Moss
Robert Rasmussen
Chris Prince
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of MX2020004218A publication Critical patent/MX2020004218A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24081ADAM10 endopeptidase (3.4.24.81)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
MX2020004218A 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10. MX2020004218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US201762589842P 2017-11-22 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Publications (1)

Publication Number Publication Date
MX2020004218A true MX2020004218A (es) 2020-11-11

Family

ID=65995419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004218A MX2020004218A (es) 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10.

Country Status (8)

Country Link
US (3) US20190345473A1 (https=)
EP (1) EP3691671A4 (https=)
JP (2) JP7448219B2 (https=)
AU (1) AU2018345601B2 (https=)
CA (1) CA3077694A1 (https=)
IL (1) IL273725A (https=)
MX (1) MX2020004218A (https=)
WO (1) WO2019070685A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512596A (ja) 2018-01-31 2021-05-20 ヴェラ セラピューティクス エルエルシー Adam9生物活性を阻害するための方法および組成物
WO2020227714A1 (en) * 2019-05-09 2020-11-12 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
US20250177333A1 (en) * 2022-03-08 2025-06-05 Nova Southeastern University Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270625A1 (en) 2002-09-11 2004-04-30 Justus-Liebig-Universität Giessen Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
ATE549028T1 (de) * 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
WO2006084075A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Adam-9 modulators
JP2008535854A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および処置におけるadam10
US7638301B2 (en) * 2006-08-28 2009-12-29 Biozyme, Inc. Prodomain modulators of ADAM 10
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US20090285640A1 (en) 2008-05-16 2009-11-19 Hilfiker William K Method for constructing a mechanically stabilized earthen embankment using semi-extensible steel soil reinforcements
EP2637679A4 (en) * 2010-11-09 2015-09-23 Univ Chicago ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASES AND THERAPEUTICS
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
WO2015117199A1 (en) 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers

Also Published As

Publication number Publication date
US20190345473A1 (en) 2019-11-14
CA3077694A1 (en) 2019-04-11
IL273725A (en) 2020-05-31
US20230203468A1 (en) 2023-06-29
EP3691671A4 (en) 2022-01-19
US12297469B2 (en) 2025-05-13
WO2019070685A1 (en) 2019-04-11
EP3691671A1 (en) 2020-08-12
US20250207119A1 (en) 2025-06-26
AU2018345601A1 (en) 2020-05-21
JP7448219B2 (ja) 2024-03-12
JP2021500321A (ja) 2021-01-07
JP2024012470A (ja) 2024-01-30
AU2018345601B2 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
UY37563A (es) Aislados de bacillus y usos de los mismos
MX356129B (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2020004218A (es) Métodos y composiciones para inhibir las actividades biológicas de adam10.
WO2015183890A3 (en) Methods and compositions for the treatment of metabolic disorders and diseases
PH12013502609A1 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
GB201001602D0 (en) Oligopeptidic compounds and uses therof
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
NZ774126A (en) Spd-1 variant - fc fusion proteins
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
NZ610620A (en) Inhibitors of apoptosis and uses thereof
PE20200894A1 (es) Polipeptidos variantes del factor de crecimiento tipo insulina 1
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
MX2015005102A (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo.
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
MX2017010259A (es) Proteina resistente a herbicidas, gen codificante y uso de los mismos.